Proc Natl Acad Sci U S A. 2015 Jan 20. pii: 201409857. Thus, activation of osteocytic β-catenin signaling increases both osteoclasts and osteoblasts, leading to bone gain, and is sufficient to activate the Notch pathway. … Leer más
FASEB J. 2015 Jan 28. pii: fj.14-259085. [Epub ahead of print] In summary, our findings demonstrate that EPO negatively regulates bone mass and thus bears significant clinical implications for the potential management of patients with … Leer más
J Bone Miner Res. 2015 Jan;30(1):3-23. doi: 10.1002/jbmr.2405. Prevention strategies for ONJ include elimination or stabilization of oral disease prior to initiation of antiresorptive agents, as well as maintenance of good oral hygiene. In those … Leer más
Cell. 2015 Jan 15;160(1-2):269-84. doi: 10.1016/j.cell.2014.11.042. Grem1 expression identifies distinct connective tissue stem cells in both the bone (OCR stem cells) and the intestine (iRSCs). Autor: Worthley DL, Churchill M, Compton JT, Tailor Y, Rao … Leer más
Although interesting data on relief of vasomotor symptoms have been reported for DT56a, further clinical studies with a greater number of cases and a longer period of study are required to correctly identify its indications … Leer más
For most conditions, the available evidence is limited. Special attention should be paid to possible contraindications of drugs used for the treatment of postmenopausal or senile osteoporosis. Bisphosphonates are the most widely used drugs in … Leer más
In conclusion, administration of oral and intravenous bisphosphonates was associated with increased bone mineral density at the lumbar spine and total hip over two years in HIV-positive patients. However, none of the included trials were … Leer más
Bone 2014; 73:1-7. doi: 10.1016/j.bone.2014.12.003. Over time, two periods of increased PHPT incidence occurred, one beginning in 1974 (121.7 per 100,000 person-years) and a second peak (86.2 per 100,000 person-years) starting in 1998. The median age of … Leer más
J Bone Miner Res. 2014 Dec;29(12):2545-51. doi: 10.1002/jbmr.2283 Percentage change from baseline in TH and FN BMD at months 12 and 24 was greater (p < 0.05) in ZOL-treated patients compared with placebo in most subgroups. Treatment-by-subgroup … Leer más
JAMA. 2014 Dec 3;312(21):2285-6. doi: 10.1001/jama.2014.14038. Although the optimal rate of bisphosphonate use in men on androgen deprivation therapy (ADT) is unknown, it is reasonable that most men with prior osteoporosis or fracture should be … Leer más
